*By Carlo Versano* Tilray, the Canadian cannabis company swiftly becoming one of the most talked-about stocks of the year, was up as much as 50 percent on Wednesday morning, leading a continued bull run in pot stocks and putting its market cap above established companies like Macy's and Viacom. Tilray President and CEO Brendan Kennedy [said](https://www.cnbc.com/2018/09/18/tilray-ceo-investing-in-pot-great-hedge-for-alcohol-drug-companies.html) on Tuesday that pharmaceutical and alcohol companies need to consider partnering with cannabis suppliers as a hedge against their core businesses. Those comments, along with the halo effect of Tilray saying it earned approval to provide medical marijuana for a U.S. clinical study, helped send shares over $200 apiece ー they debuted on the Nasdaq at $17 just two months ago. Citron Research, whose bearish bets on stocks can be market-moving, [tweeted](https://twitter.com/CitronResearch/status/1042395769372909568) on Wednesday morning that Tilray's run is "beyond comprehension" and that it will continue to be short the stock "until rationality sets in." That followed another less-than-favoratble [piece](https://www.barrons.com/articles/marijuana-stocks-coca-cola-aurora-1537235413) from Barron's that said, "even the bulls see a bubble." But with the legal sales of cannabis in Canada now less than a month away ー and investors jockeying for position ー the sector could continue on its high, at least in the short-term. Shares of both Canopy Growth and Aurora Cannabis have also seen double-digit percent increases since they've received interest from Constellation and Coca-Cola, respectively.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More